Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ImmVira Raises $10 Million for Genetically Modified Oncolytic Viruses

publication date: Sep 24, 2020

ImmVira Group, a Shenzhen biotech, raised $10 million in a Series B to develop its next-gen genetically modified oncolytic viruses for cancer. The financing was entirely funded by Shanghai Healthcare Capital, which is affiliated with Shanghai Pharma. In August, Shanghai Pharma in-licensed ImmVira's MVR-T3011 oncolytic virus program in a $165 million deal. MVR-T3011 is a genetically engineered oncolytic herpes simplex virus-1 candidate that expresses PD-1 antibody and interleukin-12 immune modulators. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital